N/A
Completed N=982
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010
Source: ClinicalTrials.gov NCT01294553 ↗Enrolled (actual)
982
Serious AEs
0.3%
Results posted
Mar 2011
Primary outcomePrimary: Number of Participants With an Adverse Event — 110 participants
Summary
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of rosiglitazone/metformin administered in Korean Diabetic patients according to the prescribing information
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With an Adverse Event |
110 | — |
| SECONDARY Number of Participants With a Serious Adverse Event |
2 | — |
| SECONDARY Number of Participants With the Indicated Unexpected Adverse Events |
42; 5; 3; 2; 2; 2 | — |
Eligibility Criteria
Inclusion criteria
- Subjects administered with rosiglitazone/metformin as an adjunct to diet and exercise for the treatment of type2 diabetes mellitus
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol and follow the administration regimen
- Subjects administered with rosiglitazone/metformin following the locally approved prescribing information
Exclusion criteria
- Subjects with previous history of hypersensitivity to rosiglitazone and/or metformin or any other ingredient
- Subjects with previous history of lactic acidosis, renal disease or renal dysfunction, hepatic dysfunction, cardiogenic shock, heart failure, myocardial infarction, pulmonary infarction and any other status with stomach upset
- Subjects with type 1 diabetes mellitus
- Subjects with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
- Subjects with severe infection, pre/post surgery, severe trauma
- Subjects with malnutrition, inanition, emaciation, pituitary insufficiency, adrenal insufficiency
- Subjects undergoing radiologic studies involving intravascular administration of iodinated contrast materials
Data sourced from ClinicalTrials.gov (NCT01294553). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.